Low Molecular Weight Heparin Market Analysis, Size, and Share by 2028

The low molecular weight heparin market is expected to grow from US$ 3,658.27 million in 2021 to US$ 5,733.96 million by 2028; it is estimated to grow at a CAGR of 6.6% from 2021 to 2028.

Low molecular weight heparin (LMWH) is a class of anticoagulants. They are used to prevent blood clots and to treat venous thromboembolism (deep vein thrombosis and pulmonary embolism) and treat myocardial infarction. LMWHs are defined as heparin salts with an average molecular weight of less than 8,000 Da and in which at least 60% of all chains have a molecular weight of less than 8,000 Da. These are obtained by various methods of fractionation or depolymerization of polymeric heparin. Low molecular weight heparin offers advantages over heparin in that it has better bioavailability and longer half-life, simplified dosing, predictable anticoagulant response, lower risk of HIT, and lower risk of osteoporosis. With a longer half-life and a more predictable anticoagulant response, LMWH can be administered subcutaneously once or twice daily without coagulation monitoring, even when the drug is administered in treatment doses. Most patients do not require coagulation monitoring with LMWH. Key factors driving the growth of the market are the advantages of low molecular weight heparin over unfractionated heparin and the introduction of LMWH anticoagulants across the globe. However, the adverse effects of low molecular weight heparin during treatment hinder the market growth.

Customize This Report To Suit Your Requirement

You will get customization on any report - free of charge - including parts of this report, or country-level analysis, Excel Data pack, as well as avail great offers and discounts for start-ups & universities

Get FREE CUSTOMIZATION

Low Molecular Weight Heparin Market: Strategic Insights

• Get Top Key Market Trends of this report.
  This FREE sample will include data analysis, ranging from market trends to estimates and forecasts.

Free Sample PDF

The low molecular weight heparin market, by region, is segmented into North America, Europe, Asia Pacific (APAC), the Middle East and Africa (MEA), and South and Central America (SAM). North America held the largest market share in 2021. The market in the region is expected to grow at the fastest pace during the forecast period. Major factors such as the growing burden of diseases, coupled with the rising geriatric population, and the rising number of approvals drive the market growth in the US. According to the Population Reference Bureau Factsheet, the number of Americans aged 65 years and above is projected to grow from 52 million in 2018 to 95 million by 2060, and the 65-and-above age group’s share of the total population is likely to rise from 16% to 23%. The geriatric population is more prone to chronic diseases. Therefore, the heparin market would grow significantly during the forecast period.

Market Insights

Advantages of Low Molecular Weight Heparin over Unfractionated Heparin

Low molecular weight heparins (LMWH) can be subcutaneously administered once a day without the need for any supervision. However, the effects of unfractionated heparin (UFH) or standard heparin vary from patient to patient. Therefore, it can only be administered to hospitalized patients under supervision. In addition, the LMWH has more predictable pharmacokinetic properties compared to unfractionated heparin, which allows its administration in fixed doses based on laboratory monitoring, without the need for dose adjustments.

The low molecular weight fractions of heparin have the molecular weight of ~3,500–8,000 Daltons, while unfractionated heparin has a molecular weight of 15,000 Daltons; thus, the former react less with platelets than the latter. Moreover, the LMWH is less likely to induce immune allergic thrombocytopenia, which is a severe side effect of unfractionated heparin (UFH). This condition is often complicated by arterial thrombosis. In addition, properties such as better bioavailability, predictable dose-response, and longer plasma half-life than unfractionated heparin make low molecular weight heparin a preferred choice for anticoagulation therapy. Such advantages of the LMWH over unfractionated heparin are boosting its demand, thereby spurring market growth.

Product Type-Based Insights

The global low molecular weight heparin market, based on product type, is segmented into enoxaparin, dalteparin, tinzaparin, fraxiparine, nadroparin, and others. The enoxaparin segment held the largest share of the market in 2021. However, the dalteparin segment is anticipated to register the highest CAGR in the market during the forecast period.

Packaging-Based Insights

The global low molecular weight heparin market, based on packaging, is bifurcated into multi-vials and prefilled syringes. In 2021, the multi-vials segment held a larger share of the market. However, the prefilled syringes segment is expected to register a higher CAGR during 2021–2028.

Application-Based Insights

The global low molecular weight heparin market, based on application, is segmented into deep vein thrombosis, acute coronary syndrome (ACS), pulmonary embolism, and others. The deep vein thrombosis segment held the largest share of the market in 2021. However, the acute coronary syndrome (ACS) segment is anticipated to register the highest CAGR in the market during the forecast period.

End Use-Based Insights

The global low molecular weight heparin market, based on end user, has been segmented into hospitals, clinics, ambulatory surgical centers, and others. The hospitals segment held the largest share of the market in 2021. However, the ambulatory surgical centers segment is anticipated to register the highest CAGR in the market during the forecast period.

The low molecular weight heparin market players adopt organic strategies, such as product launch and expansion, to expand their footprint and product portfolio worldwide and to meet the growing demand.

Market by Geography

Geographically, the low molecular weight heparin market is segmented into North America (the US, Canada, and Mexico), Europe (France, Germany, the UK, Spain, Italy, and the Rest of Europe), Asia Pacific (China, India, Japan, Australia, South Korea, and the Rest of APAC), Middle East & Africa (Saudi Arabia, the UAE, South Africa, and the Rest of MEA), and South and Central America (Brazil, Argentina, and the Rest of SCAM).

Low Molecular Weight Heparin Market Regional Insights

The regional trends and factors influencing the Low Molecular Weight Heparin Market throughout the forecast period have been thoroughly explained by the analysts at Insight Partners. This section also discusses Low Molecular Weight Heparin Market segments and geography across North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America.

Low Molecular Weight Heparin Market Report Scope

Low Molecular Weight Heparin Market Players Density: Understanding Its Impact on Business Dynamics

The Low Molecular Weight Heparin Market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.

Market players density refers to the distribution of firms or companies operating within a particular market or industry. It indicates how many competitors (market players) are present in a given market space relative to its size or total market value.

Major Companies operating in the Low Molecular Weight Heparin Market are:

1. Aspen Holdings
2. Changzhou Qianhong Bio-pharma
3. LEOPHARMA A/S
4. Teva Pharmaceutical Industries Ltd.
5. B. Braun Medical Inc.

Disclaimer: The companies listed above are not ranked in any particular order.

COVID Impacts

The spread of the COVID-19 pandemic has emphasized health data sharing and interoperability under the microscope. The infection of novel coronavirus in children is mild compared to adults, and children are assigned a better prognosis. The interruptions in the supply chain and the massive demand for efficient treatments for COVID-19 have put the health research industry in Asia-Pacific in a crucial position.

Company Profiles

• Aspen Holdings
• Changzhou Qianhong Bio-Pharma
• Leopharma A/S
• Teva Pharmaceutical Industries Ltd.
• B. Braun Medical, Inc.
• Pfizer, Inc.
• Sanofi
• Dr. Reddy's Laboratories Limited
• Abbott
• Novartis AG